Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 6/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26064318 | 0.91 | RAD51 (0.64) | RAD51GRIN2DGRIN2CGRIN2AGRIN2B | |
| SCHEMBL25430619 | 0.90 | RAD51 (0.80) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL25432853 | 0.88 | RAD51 (0.69) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL30590352 | 0.88 | RAD51 (0.69) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL25430584 | 0.85 | RAD51 (0.56) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL25433772 | 0.85 | RAD51 (0.56) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL25430581 | 0.85 | RAD51 (0.56) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL25429386 | 0.82 | RAD51 (0.62) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL30590308 | 0.82 | RAD51 (0.62) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL25433099 | 0.82 | RAD51 (0.63) | RAD51KDM4EALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | claimed |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118696034-A | Novel bicyclic compounds as RAD51 inhibitors | 萨提亚疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | RAD51 1/4885GRIN2D 2993/4885GRIN2C 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.